- Home
- SVRA vs VTYX Comparison
SVRA vs VTYX Comparison
Compare SVRA & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SVRA | VTYX |
|---|---|---|
| Founded | 2007 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 990.9M |
| IPO Year | 2009 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SVRA | VTYX |
|---|---|---|
| Price | $5.30 | $13.99 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 7 |
| Target Price | $7.33 | ★ $13.50 |
| AVG Volume (30 Days) | 1.4M | ★ 3.3M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 40.30 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.89 | $0.90 |
| 52 Week High | $7.01 | $15.34 |
Technical Indicators
Market Signals| Indicator | SVRA | VTYX |
|---|---|---|
| Relative Strength Index (RSI) | 40.47 | 72.58 |
| Support Level | $5.10 | $13.89 |
| Resistance Level | $6.06 | $14.07 |
| Average True Range (ATR) | 0.31 | 0.03 |
| MACD | -0.03 | -0.11 |
| Stochastic Oscillator | 6.42 | 88.89 |
Price Performance
Historical ComparisonAbout SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.